Advertisement

Topics

Pharnext SAS Company Profile

09:40 EST 19th January 2019 | BioPortfolio

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY©. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.


News Articles [14 Associated News Articles listed on BioPortfolio]

Pharnext: David Stout Joins Pharnext's Board of Directors

PARIS, FRANCE / ACCESSWIRE / September 17, 2018 / Pharnext SA (FR0011191287 - ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based o...

Pharnext to Present at BMO 2018 Prescriptions for Success Healthcare Conference

Dow Jones received a payment from EQS/DGAP to publish this press release. Pharnext Pharnext to Present at BMO 2018 Prescriptions for Success Healthcare Conference 10-Dec-2018 / 08:54 CET/CEST Diss...

EMA Agrees With Pharnext’s Pediatric Investigation Plan For PXT3003

NewsPXT3003 is being evaluated in an international pivotal Phase 3 clinical trial in adults with CMT1A, with top-line results expected by October 2018.

European Medicines Agency Agrees with Pharnext's Pediatric Investigation Plan for PXT3003

This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 ALPHA), a biopharmaceutical company pion...

Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer

Dow Jones received a payment from EQS/DGAP to publish this press release. Pharnext Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medic...

Pharnext partners with Galapagos

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

More Information about "Pharnext SAS" on BioPortfolio

We have published hundreds of Pharnext SAS news stories on BioPortfolio along with dozens of Pharnext SAS Clinical Trials and PubMed Articles about Pharnext SAS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharnext SAS Companies in our database. You can also find out about relevant Pharnext SAS Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record